Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Health Valued At $6 Bil. Heading Into Aug. 19 Spin-Off

Executive Summary

Medco Health's initial valuation on Wall Street is in line with the price Merck paid to acquire the pharmacy benefit management company in 1993

You may also be interested in...



Merck Succession Plan: Board Wants “Internal” Successor, CEO Says

Merck is focusing on internal candidates to succeed CEO Ray Gilmartin when he retires in 2006, Gilmartin told analysts during Merck's annual business briefing in Whitehouse Station, N.J. Dec. 9

Merck Succession Plan: Board Wants “Internal” Successor, CEO Says

Merck is focusing on internal candidates to succeed CEO Ray Gilmartin when he retires in 2006, Gilmartin told analysts during Merck's annual business briefing in Whitehouse Station, N.J. Dec. 9

Medco Eyeing “Vigorous” Public Relations Defense To False Claims Act Suit

Medco is planning an aggressive public relations defense to coincide with its legal fight against Philadelphia's U.S. Attorney

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel